SEARCH:   Advanced

Blood, 1 April 2007, Vol. 109, No. 7, pp. 2794-2796. Prepublished online as a Blood First Edition Paper on November 16, 2006; DOI 10.1182/blood-2006-07-034272. This Article Full Text Full Text (PDF) Supplemental Table All Versions of this Article: blood-2006-07-034272v1 109/7/2794    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Socie, G. Articles by Passweg, J. Search for Related Content PubMed PubMed Citation Articles by Socie, G. Articles by Passweg, J. Related Collections Hemostasis, Thrombosis, and Vascular Biology Immunobiology Red Cells Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT) Gerard Socie1, Jean-Yves Mary2, Hubert Schrezenmeier3, Judith Marsh4, Andrea Bacigalupo5, Anna Locasciulli6, Monica Fuehrer7, Albert Bekassy8, Andre Tichelli9, and Jakob Passweg10 1 Service d'Hématologie Greffe, and Institut National de la Santé et de la Recherche Médicale (INSERM) U728, Hospital Saint Louis, Paris, France; 2 INSERM U717, University Paris VII, and Département de Biostatistique et Informatique Médicale (DBIM) Hospital Saint Louis, Paris, France; 3 University of Ulm, Institute for Transfusion Medicine, and Institut für Klinische Transfusionmedizin und Immunogenetik (IKT) Ulm, Ulm, Germany; 4 Hematology, Saint George Hospital, London, United Kingdom; 5 Department of Hematology, Hospital San Martino, Genova, Italy; 6 Department of Hematology, Hospital San Camillo, Rome, Italy; 7 Children Hospital, University of Munich, Munich, Germany; 8 Department of Hematology, University Hospital, Lund, Sweden; 9 Department of Hematology, University Hospital, Basel, Switzerland; 10 Department of Hematology, Geneva Hospital, Geneva, Switzerland Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF. These results emphasize the necessity of the current European randomized trial comparing IST with or without G-CSF and to alert physicians that adding G-CSF to IST is currently not standard treatment for SAA. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Gurion, A. Gafter-Gvili, M. Paul, L. Vidal, I. Ben-Bassat, M. Yeshurun, O. Shpilberg, and P. Raanani Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis Haematologica, May 1, 2009; 94(5): 712 - 719. [Abstract] [Full Text] [PDF] J. R. Passweg and A. Tichelli Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica, March 1, 2009; 94(3): 310 - 312. [Full Text] [PDF] M. Jadersten, L. Malcovati, I. Dybedal, M. Giovanni Della Porta, R. Invernizzi, S. M. Montgomery, C. Pascutto, A. Porwit, M. Cazzola, and E. Hellstrom-Lindberg Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome J. Clin. Oncol., July 20, 2008; 26(21): 3607 - 3613. [Abstract] [Full Text] [PDF] M. Teramura, A. Kimura, S. Iwase, Y. Yonemura, S. Nakao, A. Urabe, M. Omine, and H. Mizoguchi Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan Blood, September 15, 2007; 110(6): 1756 - 1761. [Abstract] [Full Text] [PDF] B. P. Alter and P. S. Rosenberg Granulocyte colony-stimulating factor and severe aplastic anemia Blood, May 15, 2007; 109(10): 4589 - 4589. [Full Text] [PDF] A. Bacigalupo Aplastic Anemia: Pathogenesis and Treatment Hematology, January 1, 2007; 2007(1): 23 - 28. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020